Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001127602-19-029012
Filing Date
2019-09-24
Accepted
2019-09-24 16:27:41
Documents
1
Period of Report
2019-09-20

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4.html 4  
1 PRIMARY DOCUMENT form4.xml 4 3638
  Complete submission text file 0001127602-19-029012.txt   5068
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O GLYCOMIMETICS, INC. 401 PROFESSIONAL DRIVE, SUITE 250 GAITHERSBURG MD 20879
Business Address
Thackray Helen M. (Reporting) CIK: 0001589725 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-23186 | Film No.: 191111103